Bionaut labs and candel therapeutics announce strategic collaboration in precision-targeted delivery of oncolytic viral immunotherapies

Los angeles and needham, mass., dec. 15, 2021 (globe newswire) -- bionaut labs, a company focused on revolutionizing the treatment of central nervous system disorders (cns) with its bionaut™ precision medicine treatment modality, and candel therapeutics, inc. (nasdaq: cadl), a late clinical-stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced a strategic collaboration to investigate the use of bionaut's remote-controlled microscale robots for precision delivery of candel's oncolytic viral immunotherapy agents to specific brain tumors.
CADL Ratings Summary
CADL Quant Ranking